

## Livmarli<sup>®</sup> (maralixibat) – New formulation approval

- On April 14, 2025, [Mirum Pharmaceuticals announced](#) the FDA approval of [Livmarli \(maralixibat\)](#) tablets, for the treatment of:
  - Cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS)
  - Cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
- **Livmarli tablets are a new formulation of maralixibat.** Livmarli is also available as an oral solution (9.5 mg and 19 mg per mL).
- Livmarli tablets can be used for treatment of both ALGS and PFIC in patients weighing 25 kg and above who can swallow tablets. Refer to the drug label for complete dosing and administration recommendations.
- Mirum Pharmaceuticals plans to launch Livmarli tablets in June 2025. Livmarli tablets will be available in 10 mg, 15 mg, 20 mg, and 30 mg strengths.